Lv1
20 积分 2026-02-07 加入
Health-related quality of life (HRQoL) outcomes with darolutamide in the phase 3 ARANOTE trial
7个月前
已完结
Clinical outcomes of patients with metastatic Hormone-Sensitive Prostate Cancer (mHSPC) with Prostate-Specific Antigen (PSA) decline to undetectable levels on enzalutamide (ENZA): Post hoc analysis of ARCHES
7个月前
已完结
Patient-reported outcomes of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer patients (CHART): a randomized, phase 3 study
7个月前
已完结
Diagnostic Performance and Clinical Impact of 68Ga-PSMA-11 PET/CT Imaging in Early Relapsed Prostate Cancer After Radical Therapy: A Prospective Multicenter Study (IAEA-PSMA Study)
8个月前
已完结
Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer
8个月前
已完结
Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601
8个月前
已完结
皖公网安备34019202002308
